当前位置:
X-MOL 学术
›
Ther. Adva. Endocrinol. Metab.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Tolvaptan for the treatment of the syndrome of inappropriate antidiuresis (SIAD)
Therapeutic Advances in Endocrinology and Metabolism ( IF 3.8 ) Pub Date : 2023-05-16 , DOI: 10.1177/20420188231173327 Ploutarchos Tzoulis 1 , Gregory Kaltsas 2 , Stephanie E Baldeweg 3, 4 , Pierre-Marc Bouloux 5 , Ashley B Grossman 6, 7, 8
Therapeutic Advances in Endocrinology and Metabolism ( IF 3.8 ) Pub Date : 2023-05-16 , DOI: 10.1177/20420188231173327 Ploutarchos Tzoulis 1 , Gregory Kaltsas 2 , Stephanie E Baldeweg 3, 4 , Pierre-Marc Bouloux 5 , Ashley B Grossman 6, 7, 8
Affiliation
The syndrome of inappropriate antidiuresis (SIAD), the commonest cause of hyponatraemia, is associated with significant morbidity and mortality. Tolvaptan, an oral vasopressin V2-receptor antagonis...
中文翻译:
托伐普坦治疗不适当抗利尿综合征(SIAD)
不适当抗利尿综合征 (SIAD) 是低钠血症的最常见原因,与显着的发病率和死亡率有关。托伐普坦,一种口服加压素 V2 受体拮抗剂...
更新日期:2023-05-16
中文翻译:
托伐普坦治疗不适当抗利尿综合征(SIAD)
不适当抗利尿综合征 (SIAD) 是低钠血症的最常见原因,与显着的发病率和死亡率有关。托伐普坦,一种口服加压素 V2 受体拮抗剂...